Roche Holding AG’s US unit removed diversity and inclusion targets from its website, the latest in a series of publicly traded companies to bow to US President Donald Trump’s push against equal ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

An update from Roche Bobois SAS ( ($FR:RBO) ) is now available. Roche Bobois has reported its voting rights information as of January 31, 2025, ...

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

Roche (RHHBY) announced that the Food and Drug Administration has approved a New Drug Application for an Evrysdi tablet for people living with ...

Thomas Schinecker, CEO of Swiss pharma firm Roche, has dismissed fears that the company's sales targets would be threatened ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...

Boston, USA-based Newleos Therapeutics, a neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug ...

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

UBS upgraded Roche (RHHBY) to Buy from Neutral with a price target of CHF 338, up from CHF 300. The company offers sustainable growth with ...

A $30,000 scholarship programme will be launched alongside internship opportunities for science graduates as Roche Bermuda ...